Anticoagulant Treatments and Percutaneous Coronary Angioplasty (TACA)
The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2011 by Centre Hospitalier de PAU.
Recruitment status was Recruiting
Recruitment status was Recruiting
Sponsor:
Centre Hospitalier de PAU
Information provided by:
Centre Hospitalier de PAU
ClinicalTrials.gov Identifier:
NCT00669149
First received: April 25, 2008
Last updated: July 1, 2011
Last verified: July 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine whether adjunction of intravenous anticoagulant therapy (enoxaparin, HNF, bivalirudin) to antiaggregation with clopidogrel and aspirin improves in-hospital results of percutaneous transluminal coronary angioplasty (ptca) in selected patients.
| Condition | Intervention | Phase |
|---|---|---|
|
Coronary Artery Disease |
Drug: clopidogrel + aspirin Drug: heparin + clopidogrel + aspirin Drug: enoxaparin + clopidogrel + aspirin Drug: bivalirudin + clopidogrel + aspirin |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Anticoagulant Treatments Evaluation During Percutaneous Coronary Angioplasty in Stable Patients |
Resource links provided by NLM:
Further study details as provided by Centre Hospitalier de PAU:
Primary Outcome Measures:
- ischaemic events via troponin Ic measurements during 24 hours post procedure [ Time Frame: 24 hours ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- haemorrhagic events : clinical and biological evaluation [ Time Frame: 24 hours ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 480 |
| Study Start Date: | June 2008 |
| Estimated Study Completion Date: | December 2012 |
| Estimated Primary Completion Date: | August 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 1
group without anticoagulant therapy
|
Drug: clopidogrel + aspirin
Other Name: Plavix Kardégic
|
|
Active Comparator: 2
group with heparin
|
Drug: heparin + clopidogrel + aspirin
Other Name: héparine Choay Plavix Kardégic
|
|
Active Comparator: 3
group with enoxaparin
|
Drug: enoxaparin + clopidogrel + aspirin
Other Name: Lovenox Plavix Kardégic
|
|
Active Comparator: 4
group with bivalirudin
|
Drug: bivalirudin + clopidogrel + aspirin
Other Name: Angiox Plavix Kardégic
|
Detailed Description:
- Background : We don't know if using IV anticoagulant therapy is necessary for percutaneous coronary angioplasty in stable patients.
- Purpose : to compare efficacy and security of use or not of different anticoagulant treatments during percutaneous coronary angioplasty in patients with double antiaggregant therapy.
- Abstract : In stable patients pretreated with double antiaggregant therapy use of IV anticoagulants has not been yet evaluated during angioplasty. In this prospective randomized trial we want to compare in such patients the efficacy and security of the administration of IV heparin, IV enoxaparin, IV bivalirudin and no use of anticoagulant during coronary angioplasty. We will evaluate in each group ischaemic events (clinic, ECG and biology) and haemorrhagic events (clinic, biology) with a one month follow up.
- Primary outcome: ischaemic events via troponin Ic measurements during 24 hours post procedure.
- Secondary outcomes: haemorrhagic events : clinical and biological evaluation (Hb, Ht, TIMI score)
- Study design : monocentric randomized clinical trial type therapeutic equivalence phase IV.
- Interventions : In patients prepared with therapeutic association (aspirin clopidogrel) comparison between use or no of anticoagulant (IV heparin, IV enoxaparin or IV bivalirudin).
- Number of subjects : 120 per group (total of 480).
- Statistical analysis : multivariate analysis with logistic regression models : each end point (troponin Ic increase, haemoglobin decrease, …) will be explicated with treatment group and other covariates (sex, age, creatinine, …).
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- stable angina pectoris or silent ischaemia
Exclusion Criteria:
- instable angina or ACS (Acute Coronary Syndrome)
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00669149
Please refer to this study by its ClinicalTrials.gov identifier: NCT00669149
Contacts
| Contact: Nicolas DELARCHE, MD | 55-992-4883 ext 33 | n.delarche@wanadoo.fr |
Locations
| France | |
| Centre Hospitalier de Pau | Recruiting |
| PAU, Pyrénées-Atlantiques, France, 64046 | |
| Contact: Stéphane DEBEUGNY, MD 55-972-6801 ext 33 stephane.debeugny@ch-pau.fr | |
| Principal Investigator: Nicolas DELARCHE, MD | |
| Sub-Investigator: Raphaël LASSERRE, MD | |
Sponsors and Collaborators
Centre Hospitalier de PAU
Investigators
| Principal Investigator: | Nicolas DELARCHE, MD | CH de Pau |
More Information
No publications provided
| Responsible Party: | Stéphane DEBEUGNY, MD, Centre Hospitalier de PAU |
| ClinicalTrials.gov Identifier: | NCT00669149 History of Changes |
| Other Study ID Numbers: | CHPAU 2007/01 |
| Study First Received: | April 25, 2008 |
| Last Updated: | July 1, 2011 |
| Health Authority: | France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis) |
Keywords provided by Centre Hospitalier de PAU:
|
ptca antiaggregant therapy anticoagulant therapy |
Additional relevant MeSH terms:
|
Coronary Artery Disease Coronary Disease Myocardial Ischemia Arterial Occlusive Diseases Arteriosclerosis Cardiovascular Diseases Heart Diseases Vascular Diseases Anticoagulants Aspirin Clopidogrel Ticlopidine Analgesics Analgesics, Non-Narcotic Anti-Inflammatory Agents |
Anti-Inflammatory Agents, Non-Steroidal Antipyretics Antirheumatic Agents Cardiovascular Agents Central Nervous System Agents Cyclooxygenase Inhibitors Enzyme Inhibitors Fibrin Modulating Agents Fibrinolytic Agents Hematologic Agents Molecular Mechanisms of Pharmacological Action Neurotransmitter Agents Peripheral Nervous System Agents Pharmacologic Actions Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on March 01, 2015